Targeting Bcl-2 for the treatment of multiple myeloma - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Leukemia Year : 2018

Targeting Bcl-2 for the treatment of multiple myeloma


Despite advances in the treatment of multiple myeloma, the disease still remains incurable for the majority of patients. The overexpression of anti-apoptotic proteins (i.e., Bcl-2, Bcl-X L or Mcl-1) is a hallmark of cancer and favors tumor cell survival and resistance to therapy. The oral drug venetoclax is the first-in-class Bcl-2-specific BH3 mimetic. In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression. In addition with Bcl-2 members expression profile, functional tests as BH3 profiling or in vitro BH3 mimetic drug testing also predict sensitivity to the drug. Phase 1 clinical trials recently confirmed the efficacy of venetoclax monotherapy in heavily pretreated myeloma patients, mostly in patients with t(11;14). In combination with the proteasome inhibitor bortezomib, venetoclax therapy was found to be feasible and allowed promising response rate in relapsed myeloma patients, independent of t(11;14) status. The present review summarizes the current knowledge, "from bench to bedside", about venetoclax for the treatment of multiple myeloma.


Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-01885190 , version 1 (01-10-2018)



Cyrille Touzeau, Paulo Maciag, Martine Amiot, Philippe Moreau. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia, 2018, 32 (9), pp.1899 - 1907. ⟨10.1038/s41375-018-0223-9⟩. ⟨inserm-01885190⟩
61 View
2 Download



Gmail Facebook X LinkedIn More